Search by conditions:

 

Protocol Description Phase
15-105 1205-01: A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas  (View details on clinicaltrial.gov) Phase I
15-421 A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects with Relapsed or Refractory B-Cell Non-Hodgkins's Lymphoma  (View details on clinicaltrial.gov) Phase I
15-404 A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)  (View details on clinicaltrial.gov) Phase I
15-229 A Phase 1, Open-Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects with High Risk (IPI 3 Or More) Previously Untreated Diffuse Large B-Cell Lymphoma or Grade 3B Follicular Lymphoma  (View details on clinicaltrial.gov) Phase I
15-207 A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma  (View details on clinicaltrial.gov) Phase II
14-566 A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma  (View details on clinicaltrial.gov) Phase II
14-059 A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07  (View details on clinicaltrial.gov) Phase III
06-068 A Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066. A CMET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer  (View details on clinicaltrial.gov) Phase I
13-348 A Phase I Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Progressive Lymphoma  (View details on clinicaltrial.gov) Phase I
15-283 A Phase IB Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia  (View details on clinicaltrial.gov) Phase I
16-104 A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients with Previously Untreated Mantle Cell Lymphoma (MCL)  (View details on clinicaltrial.gov) Phase II
16-118 A Phase II Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma  (View details on clinicaltrial.gov) Phase II
14-296 A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia  (View details on clinicaltrial.gov) Phase II
16-329 A Randomized Double-Blinded Phase 2 Study Evaluating a Proprietary Amino Acid Mixture (Enterade├é┬«) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma  (View details on clinicaltrial.gov) Phase II
16-186 A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant  (View details on clinicaltrial.gov) Phase II
15-212 An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy  (View details on clinicaltrial.gov) Phase I
12-188 BMT CTN 1101: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic Malignancies  (View details on clinicaltrial.gov) Phase III
10-327 CALGB 50801: Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)  (View details on clinicaltrial.gov) Phase II
16-750 Molecular Analysis for Therapy Choice (MATCH)  (View details on clinicaltrial.gov) Phase II
14-242 Non-Comparative, Two-Cohort, Single Arm, Open-label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplant (ASCT)  (View details on clinicaltrial.gov) Phase II
16-272 Phase 1/2 Study of Autologous T-Lymphocytes with Antibody-Dependent Cell Cytotoxicity in Patients with Relapsed or Refractory CD20-Positive B Cell Lymphoma  (View details on clinicaltrial.gov) Phase II
17-078 Phase I Study of Venetoclax plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas  (View details on clinicaltrial.gov) Phase I
15-196 Phase II Study of Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma  (View details on clinicaltrial.gov) Phase II
23 clinical trials listed

Back to Top